Compare MKZR & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKZR | REVB |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.2M |
| IPO Year | N/A | N/A |
| Metric | MKZR | REVB |
|---|---|---|
| Price | $1.69 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.8K | ★ 42.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.47 |
| 52 Week High | $6.99 | $3.21 |
| Indicator | MKZR | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 29.74 | 42.97 |
| Support Level | $1.62 | $0.80 |
| Resistance Level | $4.03 | $1.40 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 2.54 | 9.37 |
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.